Research
Hormonal
Increased gut permeability (leaky gut) and elevated serum LPS levels are key mechanisms by which altered gut microbiota induces insulin resistance in TLR2 knockout mice.
A healthy gut barrier is essential for metabolic health. Leaky gut allows bacterial toxins (LPS) into the bloodstream, triggering inflammation that blocks insulin action. Maintaining gut integrity through diet and lifestyle is crucial for preventing insulin resistance.
GoodSupportsHIGH confidence
These changes in gut microbiota were accompanied by an increase in LPS absorption, subclinical inflammation, insulin resistance, glucose intolerance, and later, obesity.
Why this rating
Strong mechanistic evidence linking microbiota to LPS absorption and insulin resistance.
Source
Gut Microbiota Is a Key Modulator of Insulin Resistance in TLR 2 Knockout Mice
Andréa M. Caricilli et al. · PLoS Biology · 2011
DOI 10.1371/journal.pbio.1001212
mechanism_onlyCited 279×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Gut microbiota composition directly modulates insulin sensitivity in Toll-like receptor 2 (TLR2) knockout mice, where a specific microbial profile (increased Firmicutes, decreased Bifidobacterium) induces insulin resistance, glucose intolerance, and obesity, effectively reversing the genetically protected phenotype.Good
- Restoring or altering gut microbiota composition via broad-spectrum antibiotics or microbiota transplantation can reverse insulin resistance and metabolic syndrome symptoms in TLR2 knockout mice.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →